PIK3CG
ENSG00000105851
Target class
Enzyme
Chromosome
7
Approved drugs
1
Clinical candidates (approved and in development)
31
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 31
- Chemical probe available
- Yes
- Target name
- PIK3CG
- Gene name
- Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
- Gene symbol
- PIK3CG
- Protein name
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PI3Kgamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-3-kinase subunit p110-gamma) (p110gamma) (Phosphoinositide-3-kinase catalytic gamma polypeptide) (Serine/threonine protein kinase PIK3CG) (EC 2.7.11.1) (p120-PI3K)
- Gene biotype
- Protein coding
- Gene family
- Phosphatidylinositol 3-kinase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 8
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 7.5
- Tissue specificity (Gini)
- 0.645
- Tissue specificity (tau)
- 0.902
- KEGG gene identifiers
- hsa:5294
- Protein interaction confidence
- 0.861726
- Protein interaction partners
- 84
- R-HSA-114604
- R-HSA-1257604
- R-HSA-1660499
- R-HSA-2219530
- R-HSA-389357
- R-HSA-392451
- R-HSA-6811558
- R-HSA-9027276
- R-HSA-9927354
- End position
- 106908980
- Start position
- 106865278
- Chromosome
- 7
- Strand
- Forward
- Cytoplasm . Cell membrane .
- Cytosol
- Plasma membrane
Publication evidence
- PubMed 12163475
- Tissue specificity (tau)
- 0.901912
- Expression inequality (Gini)
- 0.64536
Expression in transcripts per million
- Whole Blood
- 7.5
- Spleen
- 5.79
- Testis
- 4.97
- Cells - EBV-transformed lymphocytes
- 4.37
- Lung
- 2.39
Expression in transcripts per million
- Whole Blood7.5
- Spleen5.79
- Testis4.97
- Cells - EBV-transformed lymphocytes4.37
- Lung2.39
- Small Intestine - Terminal Ileum2.24
- Adipose - Visceral (Omentum)1.21
- Adipose - Subcutaneous1.2
- Colon - Transverse0.94
- Artery - Coronary0.93
- Thyroid0.88
- Minor Salivary Gland0.79
- Breast - Mammary Tissue0.78
- Artery - Aorta0.71
- Nerve - Tibial0.68
- Cervix - Endocervix0.65
- Uterus0.61
- Bladder0.6
- Stomach0.57
- Ovary0.57
- Fallopian Tube0.55
- Prostate0.49
- Colon - Sigmoid0.49
- Brain - Spinal cord (cervical c-1)0.44
- Cervix - Ectocervix0.44
And 29 more, listed on the interactive page.
- GO:0001819
- GO:0002250
- GO:0002407
- GO:0002679
- GO:0003376
- GO:0006954
- GO:0007186
- GO:0010595
- GO:0010818
- GO:0030593
- GO:0033628
- GO:0035022
- GO:0035747
- GO:0042098
- GO:0042110
- GO:0043303
- GO:0043406
- GO:0043491
- GO:0045087
- GO:0045765
- GO:0046854
- GO:0051897
- GO:0055118
- GO:0070527
- GO:0072672
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0005944
- GO:0016020
- GO:0004672
- GO:0005515
- GO:0016303
- GO:0035005
- GO:0042802
- GO:0046875
- GO:0046934
- GO:0106310
cardiac hypertrophy
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- CV
PubMed 38773351autoimmunity
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- immune
PubMed 38773351cytogenic abnormality
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- cellular (genetic disorder)
PubMed 38773351heart disease
Studies
- preclinical: Highly important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Regulates contractility and pathological hypertrophy
Biological samples
- cardiovascular system
PubMed 21283106rash
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- skin
PubMed 38773351Decreased appetite
Effects
- Activation/Increase/Upregulation
Studies
- clinical
PubMed 38773351Hyperglycaemia
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- metabolic
PubMed 38773351pancreatic steatosis
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- pancreas
PubMed 38773351cytopenia
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- blood
PubMed 38773351weight loss
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
PubMed 38773351colitis
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- GI
PubMed 38773351lymphopenia
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- immune
PubMed 38773351breast cancer
Effects
- Activation/Increase/Upregulation
Studies
- clinical
PubMed 38773351glycosylated haemoglobin increase
Effects
- Activation/Increase/Upregulation
Studies
- clinical
Biological samples
- metabolic
PubMed 38773351hypertension
Effects
- Inhibition/Decrease/Downregulation
Studies
- clinical
Biological samples
- CV
PubMed 38773351
Related records
Trials (273)
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- 5G-PEARL: Paxalisib in Malignant Brain Tumours
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
- A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
- A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
- A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
- A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
- A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects
Drugs (34)
- Apitolisib PI3-kinase class I inhibitor
- AZD-6482 PI3-kinase class I inhibitor
- BGT-226 PI3-kinase class I inhibitor
- BGT-226 FREE BASE PI3-kinase class I inhibitor
- Buparlisib PI3-kinase class I inhibitor
- CAL-263 PI3-kinase p110-gamma subunit inhibitor
- Dactolisib PI3-kinase class I inhibitor
- DS-7423 PI3-kinase class I inhibitor
- Duvelisib PI3-kinase p110-gamma subunit inhibitor
- Duvelisib monohydrate PI3-kinase p110-gamma subunit inhibitor
- Eganelisib PI3-kinase p110-gamma subunit inhibitor
- Gedatolisib PI3-kinase class I inhibitor
- GSK-1059615 PI3-kinase class I inhibitor
- Izorlisib PI3-kinase class I inhibitor
- Omipalisib PI3-kinase class I inhibitor
- Panulisib PI3-kinase class I inhibitor
- Paxalisib PI3-kinase class I inhibitor
- PF-04691502 PI3-kinase class I inhibitor
- Pictilisib PI3-kinase class I inhibitor
- Pilaralisib PI3-kinase class I inhibitor